L-735,524 (of Merck & Co.) and 3TC (of Glaxo, Inc.) are investigational drugs which are currently being tested in adults who are infected with human immunodeficiency virus type-1 (HIV-1), the virus that causes the acquired immuno-deficiency syndrome (AIDS). The objective of this study is to evaluate the antiviral activity of the combination of L-735,524, ZDV, and 3TC in patients previously treated with ZDV alone and to assess the development of viral resistance to all three agents over 52 weeks of therapy.
Showing the most recent 10 out of 859 publications